Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells consist of a defined proportion of CD4 and CD8 positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domain and a truncated human epidermal growth factor receptor (EGFRt), which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Thesaurus).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02028455||Phase Ib/II||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells||A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia||Active, not recruiting||USA||0|